Disease and POPs

Persistent Organic Pollutants (POPs) are responsible for a wide range of metabolic diseases that clinicians in Establishment Medicine know nothing about. Even if they understood the problems POPs cause, they have no methods by which they could eliminate the threat.

I want to concentrate on some of the big diseases:

  • Obesity
  • Diabetes
  • Cardiovascular Disease
  • Cancer including Breast Cancer

The chemicals contributing to obesity are known as obesogens. Here’s something I just dug up at http://xfinity.net/blogs/lifestyle/2013/10/14/animals-are-having-an-obesity-crisis/too/

Americans aren’t the only ones getting fatter—our animals are also growing overweight, reports it isn’t just pets and lab animals piling on the pounds (though they are; the likelihood of chimps living with or near humans being obese increased tenfold between 1985 and 2005): one study found feral rats in Baltimore are also getting plumper. This is more than just an interesting piece of trivia, Pro Publica reports:

The following idea will shock people who believe we found the solution to the obesity epidemic. It raises the question of whether the usual culprits of “too much food” and “not enough exercise” are really the only things causing the obesity crisis.

And the evidence is overwhelming that it is more, much more.

Breast Cancer

Persistent organic pollutants (POPs) are a class of synthetic, lipophilic, bioaccumulative compounds, many of which were first introduced during the post WWII industrial boom. Most notable among these older POPs are dichlorodiphenyl trichloroethane (DDT) and polychlorinated biphenyls (PCBs), which were banned in the 1970s in the U.S. due to concerns over widespread human exposures and potential adverse health effects in wildlife and humans.

Because of their persistent and bioaccumulative nature, however, exposure to these compounds continues decades later with detectable levels prevalent in human tissue today. Polybrominated diphenyl ethers (PBDEs) are a newer class of POPs, introduced into the marketplace in the late 1970s as flame retardant additives to consumer and building products.   Owing to their similar molecular structure and toxicological properties to PCBs, in combination with the ubiquity of exposure, it appears PBDEs are poised to become the PCBs of the 21st century. In response to recent regulatory action that banned the use of two of the three primary commercial PBDE formulations in the U.S., replacement brominated flame retardants (BFRs) have recently emerged and are in widespread use. 

Interest in the role of POPs in breast cancer etiology stems largely from the well-documented endocrine disrupting properties of these compounds.